



Global Risks 2013 Eighth Edition

Figure 15: The Dangers of Hubris on Human Health Constellation




While viruses may capture more headlines, arguably the greatest risk of hubris to human health comes in the form of *antibiotic-resistant bacteria*. We live in a bacterial world where we will never be able to stay ahead of the mutation curve. A test of our resilience is how far behind the curve we allow ourselves to fall.

Belgian surveillance data 2011 (E. coli)




AMP: ampicillin, CHL: chloramphenicol, CIP: ciprofloxacin, COL: colistin, FFN: florfenicol, FOT: cefotaxime, GEN: gentamicin, KAN: kanamycin, NAL: nalidixic acid, SMX: sulfomethoxazole, STR: streptomycin, TAZ: ceftazidime, TET: tetracycline, TMP: trimethoprim

Belgian broilers (*E. coli*):




Vleesvarkens: *E. coli*




AMP: ampicillin, SMX: sulfomethoxazole, TET: tetracycline, NAL: nalidixic acid, STR: streptomycin, ENR¹: enrofloxacin (national monitoring report used ciprofloxacin), CHL: chloramphenicol, GEN: gentamycin, FFN: florfenicol

Linking antimicrobial use to antimicrobial resistance in 7 EU countries based on surveillance data


(a) Aminopenicillins (ampicillin)




(b) Third generation Cephalosporins (cefotaxime)




(c) Fluoroquinolons (ciprofloxacin)




(d) Amphenicols (chloramphenicol)




(e) Aminoglycosids (gentamicin)



(f) Aminoglycosids (streptomycin)




Linking antimicrobial use to antimicrobial resistance in 7 EU countries based on surveillance data



Chantziaras et al., 2013


Ecosystem

Exchange of resistance genes and bacteria between different reservoirs



BelVet-Sac

Antimicrobial use in animals in Belgium



2011-2013: - 12,7%

Antimicrobial use in Europe: EMA / ESVAC

2012

